Pain Management in Practice: Key Principles for Primary Care Providers

Primary Care Clinicians are at the front line of two powerful health challenges—managing pain responsibly while confronting the realities of opioid misuse and dependence.
Pri-Med’s Pain Management in Practice: Key Principals for PCPs delivers a dynamic, forward-thinking curriculum designed to help clinicians confidently navigate this evolving space. Clinicians will explore the newest insights in pain management, from innovative non-opioid therapies and multimodal treatment approaches to practical tools for identifying, managing, and tapering opioids safely.
Built around real-world cases, expert guidance, and evidence-based strategies, this program equips clinicians with the knowledge and skills to relieve pain, reduce risk, and elevate the quality of care for every patient.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies.
This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Begin

CME/CE Information

0 Credits - Not for CME/CE Credit

Release Date: 5/14/2026

Expiration Date: 5/14/2026

Topics

Learning Objectives

Define key concepts, mechanisms, and classifications of pain to enhance clinical understanding
Assess pain effectively while identifying risk factors for nonmedical use of opioids and substance/opioid use disorders
Evaluate evidence-based nonpharmacologic and nonopioid approaches to pain management
Review the role of opioids in pain management, including indications, limitations, and considerations for safe use
Safely initiate, adjust, and discontinue opioid therapy in patients with acute or chronic pain
Counsel patients on the safe use, storage, and disposal of opioid analgesics, including overdose reversal agents
Create personalized pain management plans integrating both opioid and nonopioid therapies
Diagnose and manage opioid use disorder, using evidence-based approaches, including referrals to specialists when needed

State Licensure Requirements

This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation. For more information, visit https://www.pri-med.com/state/state-mandated

Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.

Kentucky: This activity is approved for HB1/Prescribing Controlled Substances and 201 KAR 9:270 Addiction Medicine (MD/PA) by the Kentucky Board of Medical Licensure, ID# 1125-H2.5-PMI2025A

Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, as well as Medical Ethics and/or Professional Responsibility.

This activity satisfies training requirements for the MATE Act, which requires all DEA-registered practitioners to complete 8 hours of CME/CE credit on opioid or other substance use disorders.

Faculty

Charles E. Argoff, MD, FABPM

Vice Chair, Albany Medical College, Professor of Neurology and Urology

Director, Comprehensive Pain Center, Albany Medical Center, Director, Pain Management Fellowship, Albany, New York

Learn More

Katherine E. Galluzzi, DO, CMD, FACOFP

Professor and Chairperson, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, PA

Learn More

Oscar A. de Leon-Casasola, MD

Professor of Anesthesiology and Medicine, Senior Vice-Chair, School of Medicine and Biomedical Sciences, University of Buffalo School of Medicine

Chief, Division of Pain Medicine, Pain Medicine and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY

Learn More

Disclosures

The following relevant financial relationships have been disclosed by those in a position to influence the content of this activity. All have been mitigated by Pri-Med Institute:

Charles Argoff, MD, FABPM: Speaker for Averitas Pharma, AbbVie, Lilly, Lundbeck, Impel Pharmaceuticals, Kowa Pharmaceuticals, Nevro Corporation, Scilex Pharmaceuticals, Teva Pharmaceuticals; Researcher for AbbVie; Consultant for Collegium Pharmaceutical, Nevro Corporation, Pain Scripts, Scilex Pharmaceuticals, Shiratronics, Tris Pharma, Vertex Pharmaceuticals, Vertamical, and Xgene Pharma; Investigator for Lundbeck, and Teva Pharmaceuticals; Stock Holder for Pfizer and Trevena.

Katherine Galluzzi, DO, CMD, FACOFPT: Advisor for Eli Lilly

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC (Moderator): Consultant for OptumRx

All others in control of content for this activity have disclosed no relevant financial relationships.

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Disclaimer

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Statement of Independence

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Disclosure Policies and Contacting Pri-Med Institute

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Pain Management in Practice: Key Principles for Primary Care Providers

Begin